17.12.2015 18:00:00
|
ABIVAX to Present at the Biotech ShowcaseTM During the JP Morgan Healthcare Conference
Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will present at the Biotech Showcase™ Annual Conference, to be held in San Francisco on January 11-13, 2016.
The Biotech Showcase™ conference is one of the largest annual international healthcare conferences and will run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-14, 2016). Investors and biopharmaceutical executives from around the world gather in San Francisco during the second week of January at a series of events which are widely viewed as setting the tone for the coming year.
Professor Ehrlich’s presentation at the Biotech ShowcaseTM is scheduled as follows:
Date: | Tuesday, January 12, 2016 | ||
Time: | 10:30 AM | ||
Track: | C - Mission II (4th Floor) | ||
Venue: | Parc 55 San Francisco – Union Square | ||
55 Cyril Magnin Street, San Francisco |
Biotech Showcase™ (#BTS2016) is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its 8th year, Biotech Showcase is expected to attract upwards of 2,000 attendees.
ABIVAX (www.abivax.com)
is an emerging global leader in the discovery, development and
commercialization of anti-viral therapeutics and vaccines to treat some
of the world’s most life-threatening infectious diseases, including
HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical
stage research: ABX464 a novel first-in-class resistance-proof oral
small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that
could cure chronic Hepatitis B. ABIVAX also is advancing additional
anti-viral compounds and therapeutic vaccines that may enter the
clinical stage in the coming 18 months.
Follow us on Twitter
@ABIVAX_
View source version on businesswire.com: http://www.businesswire.com/news/home/20151217006032/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Abivax SAmehr Nachrichten
21.02.25 |
EQS-News: Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 (EQS Group) | |
28.01.25 |
EQS-News: Abivax Publishes 2025 Financial Calendar (EQS Group) | |
09.01.25 |
EQS-News: Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment (EQS Group) | |
23.12.24 |
EQS-News: Abivax Announces a Change to the Composition of its Board of Directors (EQS Group) | |
19.11.24 |
EQS-News: Abivax Establishes an At-the-Market (ATM) Program on Nasdaq (EQS Group) | |
14.11.24 |
EQS-News: Abivax presents third quarter 2024 key financial information (EQS Group) | |
13.11.24 |
EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax (EQS Group) | |
07.10.24 |
EQS-News: Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation (EQS Group) |
Analysen zu Abivax SAmehr Analysen
Aktien in diesem Artikel
Abivax SA | 7,06 | -2,35% |
|